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Charcot-Marie-Tooth disease (CMT) is a common 
inherited neurologic disorder with various modes of  
inheritance. Existing peripheral neuropathy is a generally 
accepted risk factor for increased susceptibility to 
neurotoxic agents and there is a general acceptance of  the 
 concept of  medication-induced worsening of  CMT.
 Several authors have reported vincristine neurotoxicity in 
CMT and vincristine treatment triggering the expression of  
asymptomatic CMT disease. We report the case of  a 10 
year old male patient who developed severe neuropathy 
following treatment with vincristine for his Acute 
Lymphoblastic Leukaemia. 
Methods: The case records of  the patient and a review of  
the relevant literature using available books, journals and 
online literature search was utilized.
Results: Facial nerve palsy, increasing lower extremities 
muscle weakness and abnormal gait were noticed 4 weeks 
into vincristine therapy in a ten year old male on treatment 
for acute lymphoblastic leukaemia (ALL). On a suspicion 
of  vincristine neurotoxicity, vincristine was excluded from 
his chemotherapy regimen. Although remission of  ALL 
was achieved within 6 weeks of  treatment, the patient's 
neurological symptoms did not improve even with the 
withdrawal of  vincristine. The patient was diagnosed with 
Charcot-Marie-Tooth disease resulting from vincristine 
toxicity.
Conclusion:
Patients with Charcot-Marie-Tooth disease may show 
severe toxicities with vincristine. It is therefore 
recommended that an extensive neurologic examination 
should be conducted on any paediatric patient with a 
diagnosis of  malignancy to identify any undiagnosed 
neurologic deficits and screen for suitability or otherwise of  
a vincristine containing cytotoxic therapy regimen. This 
case stresses the need for an urgent health sector response 
to provide adequate facilities for electrophysiological 
screening and genetic studies in resource limited centres 
like ours in order to identify possible cases of  undiagnosed 
CMT and prevent the occurrence of  exacerbation by 
vincristine administration. 
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INTRODUCTION
Charcot-Marie-Tooth disease (CMT) is the most common 
inherited neurologic disorder, affecting approximately 1 in 
1  2,500 people in the United States . It has various forms 
with various modes of  inheritance. CMT1 is an autosomal 
dominant disease, while CMT4 is autosomal recessive and 
1CMTX an X-linked dominant disease . Existing peripheral 
neuropathy is a generally accepted risk factor for increased 
susceptibility to neurotoxic agents and there is a general 
acceptance of  the concept of  medication-induced 
2   3-7  worsening of  CMT . Several authors , have reported 
vincristine neurotoxicity in CMT and vincristine treatment 
triggering the expression of  asymptomatic CMT disease. 
8The oldest report was from Weiden and Wright (1972)  
followed by several individual reports in the mid to late 
1980s. However, it was not until Graf  et al reported 3 cases 
2,9in 1996 that the issue gained widespread attention.
Vincristine, a widely used vinca alkaloid, is a first-line 
chemotherapeutic agent for several malignancies. The drug 
is the only agent with multiple credible examples of  
inordinate toxicity in CMT patients, which can be severe 
2and acute, in some instances after a lone exposure.  In the 
general population, a minimum total dose of  5-8mg is the 
described threshold for inducing sensory neuropathy in 
most cases. Motor involvement usually requires higher 
doses. In CMT patients, acute worsening or initiation of  
weakness, which may present sometimes as severe 
quadriparesis or a Guillain Barre-like pattern, is observed 
after administration of  only 2-4mg or the equivalent 
2 2paediatric dose of  1.5mg/m /dose.  
There is paucity of  reported cases in Nigeria. This may be 
because of  under diagnosis rather than non occurrence. We 
report a case of  vincristine induced neuropathy in a child 
with acute lymphoblastic leukaemia (ALL) and 
undiagnosed Charcot-Marie-Tooth disease.
CASE REPORT
We report the case of  a 10 year old male who presented to 
the Paediatric oncology unit of  the University of  Port 
Harcourt, teaching hospital with a 5 month history of  
generalised body pains, joint pains, recurrent fever, weight 
loss and weakness. There was no history of  trauma or 
previous blood transfusion. Systemic review revealed poor 
appetite, vomiting, gum bleeding and bone pains. The 
patient was an average primary 4 pupil; who had not 
attended school since the onset of  illness because the 
mother had to carry him about as he was too weak to walk. 
He was last of  3 children.  His elder sibling died of  sickle 
cell anaemia. There was no family history of  neuropathy. 
His mother was a 38 year old petty trader while his father, 
was a 50 year old store keeper in a health institution.
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At presentation, the patient appeared chronically ill and 
wasted, with marked pallor. He was febrile (temperature of  
o38.6 C) with generalised non tender lymphadenopathy. His 
weight was 22kg (67%) of  expected. Abdominal examination 
revealed an enlarged liver which was 4cm below the sub costal 
margin. Neurologically, the extremities were not wasted but 
muscle power was grade 3 in the right and 2 in the left lower 
limbs. 
Laboratory data revealed anaemia (packed cell volume of  
918%), leukocytosis of  16.3 x 10 /L (with 14% neutrophils, 
70% lymphocytes, 9% blasts) and thrombocytopenia of  65 x 
910 /L. Haemoglobin genotype was AA and retroviral 
screening was negative for HIV I and II. Bone marrow 
aspiration confirmed acute lymphoblastic leukaemia type L1 
(40% blasts). Serum electrolytes, urea and creatinine were 
unremarkable; however the uric acid level was elevated.
He was commenced on supportive therapy, including 
allopurinol, blood transfusions and antibiotics. Induction of  
remission was commenced four weeks after admission with 
intravenous (iv) cyclophosphamide, iv vincristine, and oral 
prednisolone. He also received intrathecal methotrexate and 
thhydrocortisone. In the 4  week of  therapy, he complained of  
heaviness of  the lower limbs, and was then noticed to fall 
easily with difficulty in standing from a squatting position. He 
also had an abnormal gait. Vincristine neurotoxicity was 
suspected and, the drug was withdrawn from his anti-cancer 
regimen and vitamin B complex was added to his 
prescriptions.
Remission was achieved after 6 weeks of  cytotoxic therapy 
and patient was discharged home to continue treatment  
consolidation phase  on outpatient basis. 
He was seen on follow up a week after discharge and noticed 
to have left facial nerve palsy. He was unable to walk 
unsupported, but could stand with support.  His lower limbs 
were jittery and easily gave way at the knee joint. He had a 
high stamping gait, with feet in the plantar flexed position and 
grade 2 muscle power in both lower limbs. Sensation was 
intact. 
He was given a one week outpatient appointment to be 
reviewed a week later, but the patient defaulted from follow 
up only to be rushed to the children's emergency Ward 4 
weeks later, with a 7 day history of  fever, gum bleeding, 
weakness and leg swelling. He had marked pallor, bilateral 
peri-orbital and pedal oedema, altered blood in the mouth 
and nostrils, hepatomegaly and splenomegaly of  12cm and 
5cm respectively. He was lethargic, had diffused tenderness 
over lower limbs and spine, and had an urgent packed cell 
volume of  17%. His primary illness ALL  had worsened and 
child died before blood could be made available for 
transfusion.
DISCUSSION
Charcot-Marie-Tooth (CMT) Disease, also known as 
Peroneal Muscular Atrophy or Hereditary Motor-Sensory 
Neuropathy (HMSN) is the most common genetically 
10determined neuropathy  and the commonest cause of  
11chronic, progressive polyneuropathy seen in children . The 
disease is named after the three physicians who first identified 
it in 1886. Jean-Martin Charcot and Pierre Marie in Paris, 
1and Howard Henry Tooth in Cambridge . It comprises a 
group of  disorders that affect peripheral nerves and presents 
with non-inflammatory degeneration of  the nerve cell body 
 12and peripheral axon or Schwann cells (myelin) . Affected 
nerves may be hypertrophic due to demyelination followed by 
13attempts at re-myelination .  Onset is usually in the first 
decade. The child presents with clumsiness and easily falls or 
trips over his/her own foot. Muscular atrophy is distal, 
accompanied by progressive weakness of  dorsi-flexion of  the 
10ankle and eventual foot drop , loss of  sensation and absent 
11reflexes .  Peroneal and tibial nerves are the earliest and most 
severely affected nerves. The process is bilateral but may be 
10slightly asymmetric . Later in the disease, weakness and 
muscle atrophy may occur in the hands, resulting in difficulty 
1with fine motor skills . The axial muscles are usually not 
involved and pain can range from mild to severe. Those 
affected have normal intelligence, normal life expectancy and 
rarely lose the ability to walk. 
3,4Several authors  have reported cases of  children with 
leukaemia who developed acute polyneuropathy after 
3treatment with vincristine. Bay et al  reported the 
development of  bilateral ptosis and complete ophtalmoplegia 
with normal papillary and corneal reflexes in a 5-year old 
thwith pre B cell ALL five days after the 4  dose of  vincristine. 
The bilateral ptosis resolved completely after 2 weeks of  
treatment with pyridoxine and pyridostigmine. 
thOur patient's symptoms worsened after the 4  dose of  
vincristine which he received weekly, following the standard 
regimen for the treatment of  ALL. Similarly, his neurological 
deterioration also involved the cranial nerves, as the patient 
developed left facial nerve palsy. 
Nearly all reports described eventual improvement with 
vincristine withdrawal or dose reduction but frequently not to 
baseline levels and most with previously unsuspected and 
2,7,9undiagnosed CMT .  Unfortunately, our patient did not live 
long enough for us to make that observation. Although he 
was commenced on Vitamin B complex which contains 
pyridoxine and vincristine withdrawn, there was no 
improvement of  the polyneuropathy, but rather a marked 
deterioration of  both neuropathy and ALL. The fact that 
patient defaulted from his treatment  probably led to a relapse 
of  his leukaemia with severe anaemia causing  further  
muscle weakness ,infiltration of  the marrow causing bone 
pains which made even more difficult for patient to stand or 
walk and eventual death  less than  2hours into  his second 
admission through the emergency.
 Many cases of  undiagnosed CMT prior to vincristine 
treatment had, in retrospect, overt clinical signs or a close 
relative with known CMT. The index case, in retrospect, 
presented with typical features of  CMT which include 
weakness of  lower limb muscles. However, the severe 
anaemia at presentation may have beclouded the suspicion of  
the likelihood of  a neurologic problem thus allowing for the 
commencement of  a vincristine- containing regimen where it 
probably should have been excluded. Medication-induced 
exacerbation of  CMT had been reported with several drugs, 
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e.g. quinidine, nifedipine, cyclosporine A, metronidazole, 
2Nitrofurantoin and Nitrous oxide . However, vincristine 
appears to be in a separate high risk category for patients with 
demyelinating forms of  CMT and the possibility of  acute 
worsening after only a single dose makes cautious 
administration problematic.
The diagnosis of  CMT begins with a standard patient history, 
family history, and neurologic examination. If  suspected, 
nerve conduction studies, electromyography, and genetic 
testing (which is   also available for some types of  CMT) 
should be done and   the diagnosis confirmed with nerve 
biopsy. In CMT, nerve conduction and electromyography 
studies are abnormal, and nerve biopsy confirms the 
1diagnosis with “onion bulb” formation.
Unfortunately, none of  the above investigations could be 
done for our case since the facilities were not immediately 
available within the hospital and his default from follow up 
compounded the issue of  Logistics. 
There is no cure for CMT, but physical therapy, occupational 
therapy, braces and other orthopaedic devices, and even 
orthopaedic surgery can help patients cope with the disabling 
symptoms of  the disease. Stabilization of  the ankle, which is 
usually the primary concern, can be achieved with stiff  boots 
in early stages and external short leg braces in advance cases. 
Surgical fusion of  the ankle may be considered. No medical 
treatment is available to arrest or slow the disease 
progression. The severity of  symptoms is quite variable in 
different patients and even among family members with the 
disease. It is difficult to establish if  this “patient's severity 
variation” contributed to the early demise of  the patient since 
he already had a terminal illness.
CONCLUSION
The diagnosis of  CMT requires a high index of  suspicion. 
This has become even very pertinent in the face of  increasing 
prevalence of  acute lymphoblastic leukaemia in children in 
our environment which implies an increasing need for 
vincristine as a first line drug in its treatment.
 
It is therefore recommended that an extensive neurologic 
examination should be conducted on any paediatric patient 
with a diagnosis of  malignancy to identify any undiagnosed 
or unidentified neurologic deficits and screen for suitability or 
otherwise of  a vincristine containing cytotoxic therapy 
regimen; and vincristine withheld from patients with an 
existing or a family history of  neuropathy. 
This case stresses the need for an urgent health sector 
r e s p o n s e  t o  p r ov i d e  a d e q u a t e  f a c i l i t i e s  f o r  
electrophysiological screening and genetic studies in resource 
limited centres like ours in order to identify possible cases of  
undiagnosed CMT and prevent the occurrence of  
exacerbation by vincristine administration. A high index of  
suspicion, increasing awareness and reporting of  
documented cases are highly valuable.
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